Gitana Scozzari

Dr. Gitana Scozzari

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2011 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
MMMario Morino
Mario Morino
MAMarco Allaix
Marco Allaix
MCMario Caldart
Mario Caldart
GSGitana Scozzari
Gitana Scozzari
AAAlberto Arezzo
Alberto Arezzo

1 June 2021 in Journal of Clinical Virology
Verified
Journal Article
Closed access
Gabriele BiancoGabriele Bianco
Gabriele Bianco
MBMatteo Boattini
Matteo Boattini
ABAnna Maria Barbui
Anna Maria Barbui
GSGitana Scozzari
Gitana Scozzari
FRFranco Riccardini
Franco Riccardini
CCCristina Costa
Cristina Costa

3 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
GSGitana Scozzari
Gitana Scozzari
CCCristina Costa
Cristina Costa
EMEnrica Migliore
Enrica Migliore
MCMaurizio Coggiola
Maurizio Coggiola
GCGiovannino Ciccone
Giovannino Ciccone
TGThe Collaborative Group
The Collaborative Group
This observational study evaluated SARS-CoV-2 IgG seroprevalence and related clinical, demographic, and occupational factors among workers at the largest tertiary care University-Hospital of Northwestern Italy and the University of Turin after the first pandemic wave of March–April 2020. Overall, about 10,000 individuals were tested; seropositive subjects were retested after 5 months to evaluate antibodies waning. Among 8769 hospital workers, seroprevalence was 7.6%, without significant differences related to job profile; among 1185 University workers, 3.3%. Self-reporting of COVID-19 suspected symptoms was significantly associated with positivity (Odds Ratio (OR) 2.07, 95%CI: 1.76–2.44), although 27% of seropositive subjects reported no previous symptom. At multivariable analysis, contacts at work resulted in an increased risk of 69%, or 24% for working in a COVID ward; contacts in the household evidenced the highest risk, up to more than five-fold (OR 5.31, 95%CI: 4.12–6.85). Compared to never smokers, being active smokers was inversely associated with seroprevalence (OR 0.60, 95%CI: 0.48–0.76). After 5 months, 85% of previously positive subjects still tested positive. The frequency of SARS-COV-2 infection among Health Care Workers was comparable with that observed in surveys performed in Northern Italy and Europe after the first pandemic wave. This study confirms that infection frequently occurred as asymptomatic and underlines the importance of household exposure, seroprevalence (OR 0.60, 95%CI: 0.48–0.76).

18 March 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CCCristina Costa
Cristina Costa
EMEnrica Migliore
Enrica Migliore
CGClaudia Galassi
Claudia Galassi
GSGitana Scozzari
Gitana Scozzari
GCGiovannino Ciccone
Giovannino Ciccone
OGon behalf of the Collaborative Group
on behalf of the Collaborative Group
We aimed at evaluating quantitative IgG response to BNT162b2 COVID-19 vaccine among health care workers (HCW), and exploring the role of demographic, clinical, and occupational factors as predictors of IgG levels. On May 2021, among 6687 HCW at the largest tertiary care University-Hospital of Northwestern Italy, at a median of 15 weeks (Interquartile range-IQR 13.6–16.0) after second-dose, serological response was present in 99.8%. Seropositivity was >97% in all the subgroups, except those self-reporting immunodeficiency (94.9%). Overall, the median serological IgG value was 990 BAU/mL (IQR 551–1870), with most of subjects with previous SARS-CoV-2 infection or with shorter time lapse (2–8 weeks) between vaccination and serology with values in the highest quintile (>2080). At multivariable analysis, significant predictors of lower values were increasing age, male, current smoking, immunodeficiency, recent occupational contacts, and increasing time lapse from vaccination; conversely, previous infection and recent household contacts were significantly associated with higher IgG levels. Subjects with previous infection kept a very high level (around 2000 BAU/mL) up to 120 days. These results, besides supporting a high serological response up to 4–5 months, suggest predictive factors of faster decay of IgG levels that could be useful in tailoring vaccination strategies.

27 June 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
CCCristina Costa
Cristina Costa
GSGitana Scozzari
Gitana Scozzari
EMEnrica Migliore
Enrica Migliore
CGClaudia Galassi
Claudia Galassi
GCGiovannino Ciccone
Giovannino Ciccone
OGon behalf of the Collaborative Group
on behalf of the Collaborative Group
We describe the results of a T-cell immunity evaluation performed after a median elapsed time of 7 months from second-dose BNT162b2 vaccine administration, in a representative sample of 419 subjects from a large cohort of hospital workers. Overall, the Quantiferon SARS-CoV-2 assay detected a responsive pattern in 49.9%, 59.2% and 68.3% of subjects to three different antigenic stimuli from SARS-CoV-2, respectively, with 72.3% of positivity to at least one antigenic stimulus. Potential predictors of cellular response were explored by multivariable analyses; factors associated with positivity to cellular response (to Ag1 antigenic stimulus) were a previous SARS-CoV-2 infection (OR = 4.24, 95% CI 2.34–7.67, p < 0.001), increasing age (per year: OR = 1.03 95% CI 1.01–1.06, p = 0.019 and currently smoking (compared to never smoking) (OR = 1.93, 95% CI 1.11–3.36, p = 0.010). Increasing time interval between vaccine administration and T-cell test was associated with decreasing cellular response (per week of time: OR = 0.94, 95% CI 0.91–0.98, p = 0.003). A blood group A/AB/B (compared to group O) was associated with higher levels of cellular immunity, especially when measured as Ag2 antigenic stimulus. Levels of cellular immunity tended to be lower among subjects that self-reported an autoimmune disorder or an immunodeficiency and among males. Further studies to assess the protective significance of different serological and cellular responses to the vaccine toward the risk of reinfection and the severity of COVID-19 are needed to better understand these findings.

13 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
EPEmanuele Pivetta
Emanuele Pivetta
ARAnna Ravetti
Anna Ravetti
GPGiulia Paglietta
Giulia Paglietta
ICIrene Cara
Irene Cara
FBFederico Buggè
Federico Buggè
ELEnrico Lupia
Enrico Lupia
During the COVID-19 pandemic, use of telemedicine with the aim of reducing the rate of viral transmission increased. This proof-of-concept observational study was planned to test the feasibility of a home-based lung ultrasound (LUS) follow-up performed by patients with mild COVID-19 infection on themselves. We enrolled patients presenting to the emergency department with SARS-CoV-2 infection without signs of pneumonia and indication to discharge. Each patient received a brief training on how to perform LUS and a handheld ultrasound probe. Then, patients were contacted on a daily basis, and LUS images were acquired by the patients themselves under “teleguidance” by the investigator. Twenty-one patients were enrolled with a median age of 44 years. All evaluations were of sufficient quality for a follow up. Probability of a better LUS quality was related to higher degree (odds ratio, OR, 1.42, 95% CI 0.5–3.99) and a lower quality to evaluation time (from 0.71, 95% CI 0.55–0.92 for less than 7 min, to 0.52, 95% CI 0.38–0.7, between 7 and 10 min, and to 0.29, 95% CI 0.2–0.43, for evaluations longer than 10 min). No effect related to gender or age was detected. LUS performed by patients and remotely overseen by expert providers seems to be a feasible and reliable telemedicine tool.